FC Basel

BeiGene is established by the European Commission for the coverage of Tislelizumab as well as the control of small organisms in the European Union.

BASEL, Switzerland, BEIJING & CAMBRIDGE, Mass. , USA, April 23, 2024–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), an oncology specialist, recently told the European Commission (EK) Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs (NSCLC) für tres indications: zugelassen hat, einschließlich als First- und Zweitlinienbehandlung.

BeiGene is established by the European Commission for the coverage of Tislelizumab as well as the control of small organisms in the European Union. Read More »